NEW YORK (GenomeWeb News) - Illumina and ReaMetrix plan to develop molecular diagnostic panels for several diseases, the companies said today.
The panels will "help predict the risk of disease, enable earlier intervention, and guide therapy," Jay Flatley, Illumina president and CEO, said in a statement.
Terms of the agreement call for Illumina to supply its VeraCode technology and other reagents while ReaMetrix will develop, validate, and market the panels.
The panels will be based on Illumina's yet-to-be-released BeadXpress platform, which the company plans to launch before the end of the year.
As part of the deal, ReaMetrix will gain non-exclusive rights to market the products in India while Illumina will be allowed to market the tests elsewhere in the world.
ReaMetrix will drive market development activities from its Bangalore, India, operation, the companies said.
Financial details were not disclosed.